Stockhead on MSN2d
The ASX players bringing new hope to IPF sufferersIdiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...
Jobs with high IPF mortality ratios differed by sex, but notable categories for both included the public administration industry and health care practitioners and technical occupations, according to ...
GlobalData on MSN3d
Qureight and Remedy Cell to validate RC-0315 in Phase Ib trial for IPFQureight and Remedy Cell have collaborated to validate the mechanism of action of RC-0315 in the Phase Ib clinical trial for ...
Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to sufferers. Characterised by the thickening and scarring of lung tissue ...
MSU's Infrastructure Planning and Facilities (IPF) released a public notice on Aug. 12, 2024 stating that they didn't take ...
GlobalData on MSN2d
Insilico raises $110m to develop drug pipeline and AI platformThe company’s focus will be on progressing the clinical validation of its idiopathic pulmonary fibrosis treatment.
IPF is a fatal, highly complex and progressive interstitial lung disease affecting approximately 3 million people worldwide. With a median survival of only 2-5 years post-diagnosis, it is ...
HealthDay on MSN2d
About 1 in 5 Idiopathic Pulmonary Fibrosis Deaths May Be Due to Occupational ExposuresAccording to a recent study, roughly one in five of idiopathic pulmonary fibrosis deaths might be related to occupational exposures.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback